The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-24 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Enslavement in the Americas existed before European arrival and was used for numerous reasons. Slavery in Mexico can be traced back to the Aztecs. Other Amerindians, such as the Inca of the Andes, the Tupinambá of Brazil, the Creek of Georgia, and the Comanche of Texas, also practiced slavery. Slavery in Canada was practiced by First Nations and by European settlers. Slave-owning people of what became Canada were, for example, the fishing societies, such as the Yurok, that lived along the Pacific coast from Alaska to California, on what is sometimes described as the Pacific or Northern Northwest Coast. Some of the indigenous peoples of the Pacific Northwest Coast, such as the Haida and Tlingit, were traditionally known as fierce warriors and slave-traders, raiding as far as California. Slavery was hereditary, the slaves being prisoners of war and their descendants were slaves. Some nations in British Columbia continued to segregate and ostracize the descendants of slaves as late as the 1970s.
==== Polish ==== Alliance of Poles in America - Founded on September 22, 1895, in Ohio as Alliance of Poles. Added "of America" in 1914. Headquarters in Cleveland. Locals are called "Groups", regional groups "Circles", and the national structure is the "Central Body", which meets quadrennially. Membership is open to both sexes from the start. Now open to anyone 15–65, of good moral character, physically and mentally healthy, Polish or Lithuanian by birth or consanguinity. Has no ritual, but it does have an oath. Had 16,000 in the late 1960s, and 20,000 in 72 locals in 1979. Had 20,000 members in 1994. Federal Life Insurance of America - Founded in 1911 as a pressure group with the US Catholic church for Polish interests. Its original name was the Federation of Polish Catholic Laymen. The insurance aspect was added in 1913, and the name changed to the Federation of Poles in America. Became Federal Life Insurance of America in 1924. Local groups are called "Lodges"; in 1979 there were 28 lodges in 7 states. The national convention meets quadrennially. Poles or people of Polish descent are eligible. A women's division was added in 1940. There were 5,000 members in 1960, and 5,543 in 1979. There were 4,476 in 1994. Sent food and clothing to Poland and Polish refugees during World War II; aided the Ochronka Orphanage in Poland since the war; also supports International Folk Fair in Milwaukee. Polish Beneficial Association - Founded in 1899 in Philadelphia and headquartered there. Locals are called "groups". National convention meets quadrennially.
Rhinoplasty, sometimes referred to as a "nose job," is a plastic surgery procedure performed to change the shape, size, or proportions of the nose or to improve nasal function and breathing. There are two types of plastic surgery used – reconstructive surgery that restores the form and functions of the nose and cosmetic surgery that changes the appearance of the nose. Reconstructive surgery seeks to resolve nasal injuries caused by various traumas including blunt, and penetrating trauma and trauma caused by blast injury. Reconstructive surgery can also treat birth defects, breathing problems, and failed primary rhinoplasties. Rhinoplasty may remove a dorsal hump, narrow the nostril width, alter the nasolabial angle, or address injuries, birth defects, or other functional issues that affect breathing, such as a deviated nasal septum, internal nasal valve collapse, or external nasal valve collapse. Surgery only on the septum is called a septoplasty. In closed rhinoplasty and open rhinoplasty surgeries – a plastic surgeon, an otolaryngologist (ear, nose, and throat specialist), or an oral and maxillofacial surgeon (jaw, face, and neck specialist), creates a functional, aesthetic, and facially proportionate nose by separating the nasal skin and the soft tissues from the nasal framework, altering them as required for form and function, suturing the incisions, using tissue glue and applying either a package or a stent, or both, to immobilize the altered nose to ensure the proper healing of the surgical incision.
Sources: en.wikipedia.org
Diabetes burden and access to care vary widely between and within countries. Between 1990 and 2022, diabetes prevalence rose faster in low and middle income countries than in high-income countries. In 2022, more than half of adults aged 30 and over with diabetes were not taking medication for it, and treatment coverage was lowest in low and middle income countries. A pooled analysis of 1,108 population-based studies estimated that in most countries, especially low and middle income ones, treatment had not increased enough to keep pace with rising prevalence, and that the gap in treatment coverage between the countries widened from 56 percentage points in women and 43 in men in 1990 to 78 and 71 respectively in 2022. WHO reported in 2021 that essential diabetes medicines were available in only about half of facilities in low and lower middle income countries, compared to about 80% of facilities globally. The International Diabetes Federation estimated that 252 million adults aged 20–79 were unaware they had diabetes in 2024. Risk also differs between ethnic groups. South Asian people tend to develop type 2 diabetes earlier in life and often at a normal body mass index. In a study of British Pakistani and British Bangladeshi participants, those with a high genetic risk of both insulin deficiency and unfavourable fat distribution were diagnosed about 8 years earlier, at a BMI about 3 kg/m² lower, than those at low genetic risk. Disparities are also documented for Indigenous peoples.
== Common names == Eurycoma longifolia is also known by the common names penawar pahit, penawar bias, bedara merah, bedara putih, lempedu pahit, payong ali, tongkat baginda, muntah bumi, petala bumi, bidara laut (all Malay-Indonesian); babi kurus (Javanese); cây bá bệnh (Vietnamese); tho nan (Laotian); lan-don, hae phan chan, phiak, plaa lai phuenk, tung saw (all Thai); "long jack" (US); langir siam (Bahrain). Many of the common names refer to the plant's medicinal use and extreme bitterness. Penawar pahit translates simply as "bitter charm" or "bitter medicine". Older literature, such as a 1953 article in the Journal of Ecology, may cite only penawar pahit as the plant's common Malay name. E. longifolia is known by common names "tongkat ali" and "pasak bumi" in the South East Asian region, but these names are also used for similar species, Polyalthia bullata. The bark and root of E. longifolia is more white/yellow-ish compared to the darker-colored P. bullata, which has led to the former being known as "tongkat ali/pasak bumi putih" or "tongkat ali/pasak bumi kuning", and the latter as "tongkat ali/pasak bumi hitam". ("Putih" means "white", "kuning" means "yellow", and "hitam" means "black" in Malay/Indonesian.) Indonesia also has a red-coloured variety known as "tongkat ali/pasak bumi merah" ("merah" meaning "red"), which is being studied by researchers and has not had its species classified. Eurycoma longifolia is also known by the species name Eurycoma longifolia Jack, as this was the name used by botanist William Jack in his taxonomical description published in 1822.
== Side effects == Common side effects of apomorphine include nausea and vomiting, particularly when starting treatment, and injection site reactions, including bruising, subcutaneous nodules, and rarely necrosis or abscesses. Other common side effects include somnolence, dizziness, and falls. Clinical reviews note that while nausea is frequently reported early during apomorphine therapy, tolerability may improve with a lower starting dose and continued use. Less common side effects include dyskinesia, orthostatic hypotension, hallucinations or psychotic-like behavior, syncope, hemolytic anemia, impulse control disorders, dose-dependent QT interval prolongation, peripheral edema, and priapism. Adverse effects are more common with continuous subcutaneous apomorphine infusion than intermittent treatment.
However, in cells lacking pyruvate carboxylase, AO monomers accumulate in the cytosol, indicating that pyruvate carboxylase has a second fully unrelated function in assembly and import. The function in AO import/assembly is fully independent of the enzyme activity of pyruvate carboxylase, because amino acid substitutions can be introduced that fully inactivate the enzyme activity of pyruvate carboxylase, without affecting its function in AO assembly and import. Conversely, mutations are known that block the function of this enzyme in the import and assembly of AO, but have no effect on the enzymatic activity of the protein. The E. coli antioxidant thioredoxin protein is another example of a moonlighting protein. Upon infection with the bacteriophage T7, E. coli thioredoxin forms a complex with T7 DNA polymerase, which results in enhanced T7 DNA replication, a crucial step for successful T7 infection. Thioredoxin binds to a loop in T7 DNA polymerase to bind more strongly to the DNA. The antioxidant function of thioredoxin is fully autonomous and fully independent of T7 DNA replication, in which the protein most likely fulfills the functional role. ADT2 and ADT5 are other examples of moonlighting proteins found in plants. Both of these proteins have roles in phenylalanine biosynthesis like all other ADTs. However ADT2, together with FtsZ is necessary in chloroplast division and ADT5 is transported by stromules into the nucleus.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.